Viktor Grunwald
Carl Neuberg Str. 1
Hannover, NI 30625, Germany
Hannover, NI 30625, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 153 publications
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).
Journal: British journal of cancer
Published: December 17, 2025
Re: Justine Panian, Caiwei Zhong, Sharon H. Choi, et al. Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.11.011.
Journal: European urology focus
Published: February 26, 2025
Contemporary treatment of metastatic clear cell renal cell carcinoma
Journal: Urologie (Heidelberg, Germany)
Published: October 11, 2024
Kick-Starting Molecular Theranostics in Renal Cell Carcinoma.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 13, 2024
Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma.
Journal: Clinical genitourinary cancer
Published: November 07, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
Journal: European urology
Published: March 31, 2023
New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer
Journal: Urologie (Heidelberg, Germany)
Published: January 24, 2023
Current concepts for perioperative systemic therapy in advanced renal cell carcinoma
Journal: Urologie (Heidelberg, Germany)
Published: October 14, 2022
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
Journal: European urology oncology
Published: July 21, 2022
Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group.
Journal: World journal of urology
Published: April 23, 2021
Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma.
Journal: European urology
Published: March 24, 2021
Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N).
Journal: Journal of cancer research and clinical oncology
Published: June 28, 2020
Last Updated: 09/26/2026